Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H48O5 |
Molecular Weight | 500.7098 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 3 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C)[C@H](C)\C=C\[C@@H](O)C(C)(C)C(=O)OC(C)C
InChI
InChIKey=AUMBXYDXKLLKEK-BGMQPCSBSA-N
InChI=1S/C31H48O5/c1-19(2)36-29(35)30(5,6)28(34)15-10-20(3)25-13-14-26-22(9-8-16-31(25,26)7)11-12-23-17-24(32)18-27(33)21(23)4/h10-12,15,19-20,24-28,32-34H,4,8-9,13-14,16-18H2,1-3,5-7H3/b15-10+,22-11+,23-12-/t20-,24-,25-,26+,27+,28-,31-/m1/s1
Molecular Formula | C31H48O5 |
Molecular Weight | 500.7098 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 3 |
Optical Activity | UNSPECIFIED |
Tisocalcitate is the vitamin D derivative. Tisocalcitate ointment is currently in phase 2 clinical development for mild to moderate psoriasis. Early studies have shown that, unlike other vitamin D3 analogues, tisocalcitate does not affect calcium metabolism. Tisocalcitate ointments were tolerated well and were safe to use on healthy skin. Tisocalcitate had been in phase II clinical trial for the treatment of psoriasis. However, this development was discontinued.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:15:23 GMT 2023
by
admin
on
Sat Dec 16 16:15:23 GMT 2023
|
Record UNII |
8O4QYK6G4Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C39713
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C66606
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
8375
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
156965-06-9
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
RR-02
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104989
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
8O4QYK6G4Y
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
300000034423
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY | |||
|
9913924
Created by
admin on Sat Dec 16 16:15:23 GMT 2023 , Edited by admin on Sat Dec 16 16:15:23 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|